Vimarsana
Biggest News Aggregation in the World

Page 2 - March Hedrick News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from March Hedrick. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In March Hedrick Today - Breaking & Trending Today

Plus Therapeutics Announces Share Repurchase Program - Plus Therapeutics (NASDAQ:PSTV) - Vimarsana News

Plus Therapeutics Announces Share Repurchase Program - Plus Therapeutics (NASDAQ:PSTV)

AUSTIN, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies

Plus Therapeutics Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium (¹⁸⁶Re) Obisbemeda in Leptomeningeal Metastases - Vimarsana News

Plus Therapeutics Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium (¹⁸⁶Re) Obisbemeda in Leptomeningeal Metastases

Cohort 4 of the ReSPECT-LM Phase 1 dose escalation trial is the first of 4 planned cohorts in Part B; the Company anticipates moving into Cohort 5...

Baystreet.ca - Plus Fails to Find Traction on Licensing Agreement - Vimarsana News

Baystreet.ca - Plus Fails to Find Traction on Licensing Agreement

Plus Therapeutics, Inc. (NASDAQ: PSTV) saw its shares continue static Friday, as the clinical-stage pharmaceutical company announced it has expanded its supply agreement with Biocept by acquiring an option to exclusively license Biocept's CNSide, a CSF-based ...

Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics - Vimarsana News

Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics

Biocept, Inc. , a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for CNSide™ with Plus Therapeutics, Inc. ,...

Baystreet.ca - Plus Fails to Find Traction on Licensing Agreement - Vimarsana News

Baystreet.ca - Plus Fails to Find Traction on Licensing Agreement

Plus Therapeutics, Inc. (NASDAQ: PSTV) saw its shares continue static Friday, as the clinical-stage pharmaceutical company announced it has expanded its supply agreement with Biocept by acquiring an option to exclusively license Biocept's CNSide, a CSF-based ...